Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress

SAN FRANCISCO, Feb. 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its financial results and pipeline progress for the year ended December 31, 2007.

"In 2007 we continued our track record of milestone achievement to advance development across our entire portfolio, and we are pleased to enter 2008 with an Alzheimer's disease product candidate in confirmatory Phase 3 development," said David T. Hung, M.D., president and chief executive officer of Medivation. "We remain committed to the rapid, efficient development of our novel product candidates for Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer to make them available to people around the world who are increasingly afflicted with these deadly and debilitating diseases for which there are still very few treatment options."

Recent Accomplishments

Alzheimer's Disease

-- Completed a double-blinded, placebo-controlled twelve month extension

of our first pivotal Alzheimer's disease (AD) trial, in which patients

continued to show statistically significant benefits on all five

clinical endpoints studied;

-- Completed a comprehensive Phase 1 clinical development program in the

U.S., which continued to show Dimebon to be safe and well tolerated;

-- Completed a successful end-of-Phase 2 meeting with the U.S. Food and

Drug Administration, which recognized our previously completed AD trial

as pivotal and allowed us to proceed to a confirmatory pivotal Phase 3


Huntington's Disease

-- In collaboration with the Huntington Study Group, began a randomized,

double-blinded, placebo-controlled Phase 1-2 trial

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
(Date:7/29/2014)... CITY, Md. , July 29, 2014 /PRNewswire/ ... announced a new and updated program for the ... 10 – 12, 2014 in Amelia Island ... CROs, sites and investigators remains unchanged, however, the ... purposeful exchange and networking opportunity among all stakeholders ...
(Date:7/29/2014)... According to the new research ... (Image Analysis Software), Delivery Modes (Web Based/Cloud Based) & ... to 2018", published by MarketsandMarkets, analyzes and studies the ... North America , Europe ... Rest of the World (RoW). Browse 78 ...
(Date:7/29/2014)... PORTLAND, Oregon , July 29, 2014 ... titled, "Global surgical equipment market (types, applications and geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... expected to reach $12.1 billion by 2020 registering a ... Due to the breakthrough achieved by the electro surgical ...
(Date:7/29/2014)... July 29, 2014 TransVac Solutions, the ... collection and transport solutions for hospitals, will be exhibiting ... Engineering (ASHE) Annual Conference & Technical Exhibition Aug. 3-6 ... its technology for making hospitals cleaner, reducing infection risk ... the hospital’s life cycle. Staff will be available ...
Breaking Biology Technology:TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
... Nov. 17 Doctors Research Group, Inc. announced today ... Food and Drug Administration (FDA) to market KRYPTONITE(TM) Bone ... a major advancement in treating cranial defects due to ... exotherm cement and bone void filler approved for cranioplasty ...
... , SAN FRANCISCO, Nov. 17 Merriman Curhan Ford Group, ... in PolyMedix Inc.,s (OTC Bulletin Board: PYMX) $20.7 million registered ... priced at $1.00 per unit, consist of one share of ... 0.30 of a share of PolyMedix common stock at $1.25 ...
... TSX symbol: SBS , CALGARY, Nov. 17 /PRNewswire-FirstCall/ - ... Court of Queen,s Bench of Alberta has issued an ... of the securityholders of SemBioSys, at which securityholders will ... (the "Arrangement") involving the corporate reorganization with Cathedral Energy ...
Cached Biology Technology:Doctors Research Group Receives FDA Clearance for U.S. Distribution of KRYPTONITE(TM) Bone Cement 2Merriman Curhan Ford Acted as Lead Placement Agent in PolyMedix's $20.7 Million Equity Financing 2SemBioSys securityholder vote to be held December 18, 2009 with a record date of November 16, 2009 2SemBioSys securityholder vote to be held December 18, 2009 with a record date of November 16, 2009 3
(Date:7/29/2014)... With thirty days to go and almost 2500 ... Conference are well underway. The event, a joint venture ... and the French Society for Biochemistry and Molecular Biology ... Thursday, 4 September at the Palais des Congrs in ... largest meeting for the life sciences in Europe this ...
(Date:7/29/2014)... Achalasia is a rare disease it affects 1 in ... in the esophageal wall. While its cause remains unknown, a ... in Belgium, the University of Bonn in Germany and other ... autoimmune in origin. The study, published on 6 July in ... the mysterious disease. , When we swallow, a sphincter in ...
(Date:7/28/2014)... About 100 drugs already approved by the U.S. Food ... prevent the growth of certain bacterial pathogens inside human ... Mediterranean spotted fever. The findings, published in mBio ... for Microbiology, demonstrate a new way of identifying non-antibiotic ... , A handful of drugs on the list ...
Breaking Biology News(10 mins):Counting down to FEBS-EMBO 2014 in Paris, France 2Mysterious esophagus disease is autoimmune after all 2New route to identify drugs that can fight bacterial infections 2
... Deepwater Horizon oil spill, a UC Santa Barbara scientist has ... oil will spread. He was able to forecast several days in ... parts of the Gulf of Mexico. "We predicted where the ... mechanical engineering at UC Santa Barbara who studies fluid dynamics. "We ...
... Singapore, September 3, 2010 Novartis announced today ... (NITD), in collaboration with researchers from the Genomics Institute ... and Public Health Institute and The Scripps Research Institute ... a next generation treatment for drug resistant malaria. Major ...
... N.Y. -- Twenty-first-century pharmaceutical breakthroughs require 21st-century drug ... molecular design and high-throughput screening of effective, new ... Buffalo symposium to be held Sept. 11 on ... Screening," which will feature a variety of cutting-edge ...
Cached Biology News:New method successfully predicted how oil from Deepwater Horizon spill would spread 2Novartis and collaborators discover novel antimalarial drug candidate 2Novartis and collaborators discover novel antimalarial drug candidate 3University at Buffalo symposium on in silico methods, high throughput screening 2University at Buffalo symposium on in silico methods, high throughput screening 3
... refrigerators, freezers, or liquid nitrogen. Conveniently sized to fit ... coding to project, user, lab, etc. Holes in the ... circulation. Supplied with 9 x 9 (12.7 mm cell) ... 13 x 13 x 5.1 cm H (5 1/4 ...
Recombinant Rhesus Monkey IFN-Alpha...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
Biology Products: